Therefore, our results indicate that Cystatin SN expression combined with clinicopathological parameters may serve as an extra factor for identifying ESCC patients with a higher risk of tumor recurrence and metastasis. This evidence concerns the gene CST4 and esophageal squamous cell carcinoma.